NDAORALTABLET, ORALLY DISINTEGRATING
Approved
Jul 2007
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
6
Data completeness
4/8 — Partial
CHILDREN'S ALLEGRA ALLERGY (fexofenadine hydrochloride) by Sanofi. Approved for these symptoms due to hay fever, other upper respiratory allergies: runny nose sneezing itchy, water eyes itching of the nose and 1 more indications. First approved in 2007.
Drug data last refreshed 1w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Children's Allegra Allergy is an oral antihistamine tablet formulation of fexofenadine hydrochloride indicated for relief of symptoms associated with hay fever and upper respiratory allergies in pediatric patients. It treats runny nose, sneezing, itchy/watery eyes, and throat itching through selective H1-receptor antagonism. The orally disintegrating tablet formulation is designed for easy pediatric administration.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30%); expect transition from peak revenue defense to lifecycle extension strategies and eventual generic transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Worked on CHILDREN'S ALLEGRA ALLERGY at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.